Product
Ziftomenib
Aliases
KO-539
8 clinical trials
26 indications
Indication
Advanced Malignant NeoplasmIndication
Acute Myeloid LeukemiaIndication
Mixed Lineage LeukemiaIndication
Mixed Lineage Acute LeukemiaIndication
Acute Leukemia of Ambiguous LineageIndication
Mixed Phenotype Acute LeukemiaIndication
Mixed Lineage Leukemia Gene MutationIndication
AML with Mutated NPM1Indication
RelapseIndication
NPM1 MutationIndication
KMT2AIndication
Myeloid SarcomaIndication
KMT2A-r Acute LeukemiaIndication
Refractory Acute LeukemiaIndication
Pediatric RelapsedIndication
Acute Lymphoblastic LeukemiaIndication
acute myeloid leukemiaIndication
hematologic malignanciesIndication
MLL RearrangementIndication
LeukemiaIndication
myeloidIndication
AcuteIndication
NeoplasmsIndication
KMT2A RearrangementClinical trial
A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase 1 Trial of Menin-inhibitor Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory KMT2A-r/NUP98-r/NPM1-m Acute LeukemiaStatus: Not yet recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute LeukemiasStatus: Not yet recruiting, Estimated PCD: 2028-12-31
Clinical trial
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIStatus: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid LeukemiaStatus: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
An Open Label Phase I Study of Ziftomenib as Maintenance Therapy Following Allogeneic Hematopoietic Cell TransplantationStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2028-12-31